Johnson & Johnson

09/17/2021 | Press release | Distributed by Public on 09/17/2021 07:01

Janssen Receives Positive CHMP Opinion for BYANNLI® (6-monthly Paliperidone Palmitate) for the Maintenance Treatment of Schizophrenia in Adults